TiGenix participates in key conferences in the first half of 2016
(Thomson Reuters ONE) -
Leuven (BELGIUM) - January 8, 2016, 7:00h CET - TiGenix NV (Euronext Brussels:
TIG), an advanced biopharmaceutical company focused on developing and
commercialising novel therapeutics from its proprietary platforms of allogeneic
expanded stem cells, announced today the key conferences in which it is going to
participate during the first half of 2016.
25-27January
Phacilitate Cell & Gene Therapy World, Washington, USA
Presenter (to be confirmed): Marie-Paule Richard, Chief Medical Officer
16-19 March
11(th) Congress of ECCO (European Crohn's and Colitis Organisation, Amsterdam,
The Netherlands
Participants: Eduardo Bravo, Chief Executive Officer; Claudia D'Augusta, Chief
Financial Officer; Wilfried Dalemans, Chief Technical Officer; Marie-Paule
Richard, Chief Medical Officer; Maria Pascual, Vice President Regulatory Affairs
and Corporate Quality; Mary Carmen Diez, Vice President Medical Affairs and New
Product Commercialisation
22 March
4th Annual Regen Med Investor Day, New York, USA
Presenter: Eduardo Bravo, Chief Executive Officer
22 March
KBC Securities Benelux Biotech & Healthcare Conference, Brussels, Belgium
Participant: Claudia D'Augusta, Chief Financial Officer
2-4 April
ACC: American College of Cardiology, Chicago, USA
Participant (to be confirmed): Marie-Paule Richard, Chief Medical Officer
4-6 April
BIO-Europe Spring, Stockholm, Sweden
Participant: Miguel Mulet, Director of Strategy and New Projects
6-7 April
Kempen & Co Healthcare & Life Sciences, Amsterdam, Netherlands
Participant: Claudia D'Augusta, Chief Financial Officer
6-8 April
DIA - 28th Annual EuroMeeting, Hamburg, Germany
Participants: Maria Pascual, Vice President Regulatory Affairs and Corporate
Quality
6-7 April
ARM's EU Advanced Therapies Summit, Stockholm, Sweden
Participants: Eduardo Bravo, Chief Executive Officer; Wilfried Dalemans, Chief
Technical Officer;
25-27 April
Stem Cell Summit 2016, Boston, USA
Participants (to be confirmed): Eduardo Bravo, Chief Executive Officer
12-13 May
12th Symposium on stem cell therapy and cardiovascular innovations, Madrid,
Spain
Participants: Marie-Paule Richard, Chief Medical Officer; Miguel Mulet, Director
of Strategy and New Projects
18-20 May
World Stem Cells & Regenerative Medicine, London, UK
Participants: Eduardo Bravo, Chief Executive Officer; Miguel Mulet, Director of
Strategy and New Projects
21-24 May
Digestive Disease Week, San Diego-California, USA
Participants: Mary Carmen Diez, Vice President Medical Affairs and New Product
Commercialization
6-9 June
BIO International Convention, San Francisco, USA
Participant: Miguel Mulet, Director of Strategy and New Projects
7-8 June
PDA: Advanced Therapy Medicinal Products, Berlin, Germany
Participants: Wilfried Dalemans, Chief Technical Officer; Maria Pascual, Vice
President Regulatory Affairs and Corporate Quality
For more information, please contact:
TiGenix
Claudia D'Augusta
Chief Financial Officer
T: +34 91 804 92 64
claudia.daugusta(at)tigenix.com
About TiGenix
TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company
focused on developing and commercialising novel therapeutics from its
proprietary platforms of allogeneic, or donor-derived, expanded stem cells. Two
products from the adipose-derived stem cell technology platform are currently in
clinical development. Cx601 is in Phase III for the treatment of complex
perianal fistulas in Crohn's disease patients. Cx611 has completed a Phase I
sepsis challenge trial and a Phase I/II trial in rheumatoid arthritis. Effective
July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product,
AlloCSC-01, is currently in a Phase II clinical trial in acute myocardial
infarction (AMI). In addition, the second product candidate from the cardiac
stem cell-based platform acquired from Coretherapix, AlloCSC-02, is being
developed in a chronic indication. TiGenix also developed ChondroCelect, an
autologous cell therapy product for cartilage repair of the knee, which was the
first Advanced Therapy Medicinal Product (ATMP) to be approved by the European
Medicines Agency (EMA). From June 2014, the marketing and distribution rights of
ChondroCelect were exclusively licensed to Sobi for the European Union (except
for Finland, where it is distributed by the Finnish Red Cross Blood Service),
Norway, Russia, Switzerland and Turkey, and the countries of the Middle East and
North Africa. TiGenix is headquartered in Leuven (Belgium) and has operations in
Madrid (Spain).
Forward-looking information
This press release may contain forward-looking statements and estimates with
respect to the anticipated future performance of TiGenix and the market in which
it operates. Certain of these statements, forecasts and estimates can be
recognised by the use of words such as, without limitation, "believes",
"anticipates", "expects", "intends", "plans", "seeks", "estimates", "may",
"will" and "continue" and similar expressions. They include all matters that are
not historical facts. Such statements, forecasts and estimates are based on
various assumptions and assessments of known and unknown risks, uncertainties
and other factors, which were deemed reasonable when made but may or may not
prove to be correct. Actual events are difficult to predict and may depend upon
factors that are beyond the Company's control. Therefore, actual results, the
financial condition, performance or achievements of TiGenix, or industry
results, may turn out to be materially different from any future results,
performance or achievements expressed or implied by such statements, forecasts
and estimates. Given these uncertainties, no representations are made as to the
accuracy or fairness of such forward-looking statements, forecasts and
estimates. Furthermore, forward-looking statements, forecasts and estimates only
speak as of the date of the publication of this press release. TiGenix disclaims
any obligation to update any such forward-looking statement, forecast or
estimates to reflect any change in the Company's expectations with regard
thereto, or any change in events, conditions or circumstances on which any such
statement, forecast or estimate is based, except to the extent required by
Belgian law.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: TiGenix via GlobeNewswire
[HUG#1977348]
Unternehmensinformation / Kurzprofil:
Datum: 08.01.2016 - 07:00 Uhr
Sprache: Deutsch
News-ID 443075
Anzahl Zeichen: 7596
contact information:
Town:
Leuven
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 245 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"TiGenix participates in key conferences in the first half of 2016"
steht unter der journalistisch-redaktionellen Verantwortung von
TiGenix (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
